BOSTON—Barbara Weber, the Chief Executive Officer of Tango Therapeutics, Inc. (NASDAQ:TNGX), a $350 million market cap biotech company, recently sold a portion of her holdings in the company.

Christophe Weber will step down as CEO of Takeda next year, the company announced, following a dropoff in its share price ...

Steven Weber, the Principal Accounting Officer ... Truist Securities maintained a Hold rating on the stock but drastically reduced the price target from $12.00 to $2.00. Similarly, Morgan Stanley ...